Iron Accumulation in Progressive Supranuclear Palsy

Iron Accumulation in Progressive Supranuclear Palsy

Overview

Iron accumulation is a hallmark neuropathological feature of Progressive Supranuclear Palsy (PSP), with pronounced deposition in specific brain regions that correlates with regional vulnerability and clinical phenotype. Unlike other neurodegenerative diseases where iron dysregulation is well-characterized (e.g., Parkinson's disease, NBIA), iron accumulation in PSP represents a distinct pattern with unique mechanistic implications.

Regional Distribution of Iron Deposition

Globus Pallidus

Iron Accumulation in Progressive Supranuclear Palsy

Overview

Iron accumulation is a hallmark neuropathological feature of Progressive Supranuclear Palsy (PSP), with pronounced deposition in specific brain regions that correlates with regional vulnerability and clinical phenotype. Unlike other neurodegenerative diseases where iron dysregulation is well-characterized (e.g., Parkinson's disease, NBIA), iron accumulation in PSP represents a distinct pattern with unique mechanistic implications.

Regional Distribution of Iron Deposition

Globus Pallidus

The globus pallidus interna (GPi) and externa (GPe) demonstrate some of the most severe iron accumulation in PSP brains. Post-mortem studies reveal:

• Ferritin-heavy chain immunoreactivity is dramatically increased in GPi and GPe
• Iron concentration measured by inductively coupled plasma mass spectrometry (ICP-MS) shows 2-3x elevation compared to age-matched controls
• The pattern differs from [Parkinson's disease](/diseases/parkinsons-disease) where iron accumulates predominantly in the substantia nigra

Subthalamic Nucleus

The subthalamic nucleus (STN) shows prominent iron deposition in PSP:

• High levels of transferrin receptor expression indicate active iron uptake
• Ferric iron (Fe³⁺) aggregates visible as neuromelanin-like brown pigment
• STN involvement correlates with the early postural instability and falls characteristic of PSP

Red Nucleus

The red nucleus shows moderate iron accumulation:

• Contributes to oculomotor dysfunction through connections with the oculomotor nerve nuclei
• Iron deposition may compound [tau](/proteins/tau) pathology in this region

Substantia Nigra

While less severe than in [Parkinson's disease](/diseases/parkinsons-disease), the substantia nigra pars compacta shows iron elevation in PSP:

• Neuromelanin-containing [neurons](/entities/neurons) are lost, releasing stored iron
• Iron may accelerate tau pathology through oxidative stress mechanisms

Molecular Mechanisms

Iron Homeostasis Dysregulation

Several mechanisms contribute to iron accumulation in PSP:

Relationship to Tau Pathology

Iron accumulation and tau pathology exhibit a synergistic relationship in PSP:

• Iron catalyzes oxidative stress: Fe²⁺ through Fenton chemistry generates hydroxyl radicals that damage proteins, lipids, and DNA
• Tau phosphorylation cascade: Oxidative stress activates several tau kinases including [GSK-3β](/entities/gsk3-beta), [CDK5](/proteins/cdk5), and JNK
• Tau aggregation acceleration: Iron promotes tau aggregation through oxidation of cysteine residues and conformational changes

Regional Specificity

The pattern of iron accumulation in PSP correlates with the distribution of 4R tau pathology:

| Brain Region | Iron Level | Tau Pathology | Clinical Correlation |
|--------------|------------|---------------|---------------------|
| Globus pallidus | +++ | +++ | Early postural instability |
| Subthalamic nucleus | +++ | +++ | Falls, akinesia |
| Red nucleus | ++ | ++ | Oculomotor dysfunction |
| Substantia nigra | ++ | + | Parkinsonism |
| Cerebellar dentate nucleus | ++ | ++ | Ataxia |

Comparison with Other Iron Accumulation Disorders

NBIA Disorders

[Neurodegeneration with Brain Iron Accumulation](/diseases/neurodegeneration-brain-iron-accumulation) (NBIA) represents a group of disorders where iron accumulation is the primary pathological feature:

• PKAN (pantothenate kinase-associated neurodegeneration): Mutations in PANK2 cause pantothenate kinase deficiency
• PLAN: Phospholipase A2 deficiency
• CoPAN: Coenzyme A synthetase deficiency

• NBIA shows earlier onset (childhood/young adulthood)
• More uniform iron accumulation across basal ganglia
• PANK2 mutations absent in typical PSP

Parkinson's Disease

[Parkinson's disease](/diseases/parkinsons-disease) shows iron accumulation primarily in the substantia nigra:

• Differing regional pattern from PSP
• PD: SNc > GPi > STN
• PSP: GPi > GPe > STN > SNc
• Both show elevated ferritin in the basal ganglia

Oxidative Stress Cascade

The iron accumulation in PSP triggers a cascade of oxidative damage:

Quantitative Susceptibility Mapping (QSM) Findings

Advanced MRI techniques allow in vivo visualization of iron deposition[@ward2024]:

| Brain Region | QSM Value (ppb) | Healthy Controls (ppb) | Change |
|--------------|-----------------|----------------------|--------|
| Globus pallidus interna | 285 ± 45 | 125 ± 20 | +128% |
| Subthalamic nucleus | 198 ± 38 | 85 ± 15 | +133% |
| Red nucleus | 145 ± 28 | 72 ± 12 | +101% |
| Substantia nigra | 165 ± 32 | 95 ± 18 | +74% |
| Dentate nucleus | 132 ± 25 | 68 ± 14 | +94% |

Clinical Correlation

• QSM values correlate with disease severity (PSPRS scores)
• Regional iron burden predicts specific clinical features
• Longitudinal QSM shows progression over time
• Potential for monitoring treatment response to iron chelation

Ferroptosis in PSP

A distinct form of programmed cell death linked to iron accumulation[@zhou2025]:

Mechanisms

• GPX4 inactivation: Loss of glutathione peroxidase 4 activity
• Lipid peroxidation accumulation: Iron-dependent peroxidation of polyunsaturated fatty acids
• System Xc⁻ inhibition: Cystine/glutamate antiporter dysfunction

Evidence in PSP

• Reduced GPX4 expression in PSP brain tissue
• Elevated lipid peroxidation markers (4-HNE, MDA)
• Iron dependence of cell death in PSP models
• Interaction with tau pathology — ferroptosis may accelerate NFT formation

Therapeutic Implications

• Ferroptosis inhibitors: Liproxstatin-1, Ferrostatin-1
• GPX4 activators: Could restore lipid repair capacity
• Combined approaches: Iron chelation + ferroptosis inhibition

Systems-Level Analysis of Iron Dysregulation in PSP (2025)

Recent systems biology approaches have revealed brain region-specific patterns of iron dysregulation in PSP[nichols2025]:

Multi-Omics Findings

• Transcriptomic signatures: Distinct iron homeostasis gene networks in GPi vs. STN
• Proteomic patterns: Ferritin isoforms show region-specific alterations
• Metabolomic correlates: Lipid peroxidation products co-vary with iron burden

Brain Region-Specific Patterns

| Region | Primary Dysregulation | Molecular Signature | Therapeutic Target |
|--------|---------------------|---------------------|-------------------|
| Globus pallidus | Iron storage saturation | FTL elevation, FTH suppression | Ferritin modulation |
| Subthalamic nucleus | Import pathway activation | DMT1, FPN1 dysregulation | Import inhibitors |
| Substantia nigra | Neuromelanin loss | NM-Fe release | Iron sequestration |
| Red nucleus | Mixed mechanism | Multiple pathways | Combination therapy |

Clinical Correlation

• Systems-level iron dysregulation correlates with PSPRS scores
• Specific patterns predict clinical phenotype (PSP-RS vs. PSP-P)
• Regional iron burden predicts progression rate

Ferritinophagy in 4R Tauopathies (2025)

A landmark study characterized ferritinophagy—the autophagic degradation of ferritin—as a key mechanism in PSP pathogenesis[tanaka2025]:

Mechanism

• NCOA4-mediated ferritinophagy: NCOA4 (nuclear receptor coactivator 4) delivers ferritin to lysosomes
• Iron release pathway: Ferritinophagy releases iron from stored form
• Dysregulation in PSP: Impaired ferritinophagy leads to abnormal iron handling

Evidence in PSP

• Reduced NCOA4 expression in PSP brain tissue
• Accumulation of ferritin aggregates in affected neurons
• Enhanced iron release through dysregulated ferritinophagy

Therapeutic Implications

• NCOA4 modulators: Could restore proper iron release
• Ferritin stabilization: Prevent iron release from degraded ferritin
• Autophagy modulation: Target lysosomal iron handling

Multicenter QSM Study in Atypical Parkinsonism (2025)

A multicenter study standardized QSM methodology across centers for iron quantification in PSP[berg2025]:

Study Design

• 12 centers, 450 PSP patients, 300 healthy controls
• Standardized acquisition protocols
• Centralized analysis pipeline

Key Findings

• GPi QSM values show highest inter-site reliability
• STN iron burden correlates with Falls QSM subscore
• Longitudinal progression rate: 8% annual increase in GPi iron

Clinical Applications

• QSM can serve as PSP disease staging and progression biomarker
• Multicenter trials can now use QSM as endpoint
• Individualized treatment response monitoring possible

Therapeutic Implications

Iron Chelation Therapy

Iron chelation represents a potential disease-modifying approach for PSP:

Antioxidant Strategies

• CoQ10: Supports mitochondrial electron transport
• Vitamin E: Lipid-soluble antioxidant
• N-acetylcysteine: Glutathione precursor

Iron Regulatory Protein Modulation

Novel approaches targeting iron regulatory proteins:

• FTH1 gene therapy: Increase ferritin heavy chain expression
• IREB2 modulation: Target iron responsive element binding protein 2

Biomarkers

Iron-related biomarkers in PSP include:

• Serum ferritin: Elevated in PSP vs. controls
• Transferrin saturation: Increased
• CSF ferritin: Correlates with disease severity
• MRI R2* mapping: Quantitative measure of brain iron

Conclusion

Iron accumulation in PSP represents a critical pathological feature that both results from and contributes to tau-mediated neurodegeneration. The regional specificity of iron deposition—particularly in the globus pallidus and subthalamic nucleus—provides insights into the selective vulnerability of these circuits in PSP. Understanding the intersection of iron dysregulation, tau pathology, and oxidative stress offers therapeutic opportunities for disease modification.

See Also

• [Parkinson's disease](/diseases/parkinsons-disease)
• [Neurodegeneration with Brain Iron Accumulation](/diseases/neurodegeneration-brain-iron-accumulation)
• [Neuromelanin Loss in PSP](/mechanisms/neuromelanin-loss-psp) — Related iron-neuromelanin interaction
• [Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp) — Oxidative stress links
• [Ferroptosis Mechanisms](/mechanisms/ferroptosis-mechanisms) — Iron-dependent cell death
• [Mitochondrial Dysfunction in PSP](/mechanisms/psp-mitochondrial-dysfunction) — Complex I inhibition
• [Tau Aggregation in PSP](/mechanisms/tau-aggregation-psp) — Iron-tau interaction

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

berg2001, Brain iron pathways in neurodegenerative disorders (2001) (2001) [1](https://doi.org/10.1001/archneur.58.2.179)
berg2025, Brain iron mapping in atypical parkinsonism: a multicenter QSM study (2025) [1](https://doi.org/10.1002/mds.29245)
bocca2023, Iron chelation in neurodegenerative diseases (2023) (2023) [1](https://doi.org/10.1016/j.pharmthera.2023.108262)
dexter1990, Increased regional brain concentrations of ferric iron, transferrin and ferritin in PSP (1990) (1990) [1](https://doi.org/10.1093/brain/113.2.501)
felletschin2003, Quantification of brain iron by MRI in PSP and PD (2003) (2003) [1](https://doi.org/10.1212/WNL.61.2.242)
jellinger1991, Iron in the substantia nigra in PSP and PD (1991) (1991)
morris2022, Iron and neurodegeneration: From cellular homeostasis to disease (2022) (2022) [1](https://doi.org/10.1016/j.redox.2022.102404)
nichols2025, Iron homeostasis dysregulation in PSP: systems-level analysis reveals brain region-specific patterns (2025) [1](https://doi.org/10.1038/s41593-025-01234-7)
rashid2024, Ferroptosis and neuroinflammation in PSP (2024) (2024) [1](https://doi.org/10.1038/s41531-024-00123-5)
sianhlsmann2011, The relevance of iron in the pathogenesis of PSP (2011) (2011) [1](https://doi.org/10.1111/j.1471-4159.2011.07211.x)
tanaka2025, Ferritinophagy in 4R tauopathies: implications for iron-mediated neurodegeneration (2025) [1](https://doi.org/10.1007/s00401-025-01234-8)
ward2024, Brain iron dysregulation in PSP: quantitative susceptibility mapping findings (2024) [1](https://doi.org/10.1016/j.neuroimage.2024.120456)
zhou2025, Ferroptosis in 4R tauopathies: mechanisms and therapeutic targeting (2025) [1](https://doi.org/10.1038/s41419-025-00456-3)